Informations générales (source: ClinicalTrials.gov)
Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature (NMDARE-HSE)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
avril 2020
octobre 2020
29 juin 2024
Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an
estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries.
Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of
5 to 20% and a considerable morbidity rate.
One of the contributing factors of bad prognosis is the development of encephalitis
mediated by autoantibodies, most often directed against NMDA receptors, in the weeks
following viral encephalitis.
The description of this pathology is recent, the pathophysiology of this process remains
poorly understood, and the management of these patients is not yet codified.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospice Civils de Lyon - 69500, - Bron - France | JEROME HONNORAT, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in
the CSF
- After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
- Without age limit
Exclusion Criteria- No respect of inclusion criteria
- Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in
the CSF
- After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
- Without age limit
Exclusion Criteria- No respect of inclusion criteria